Previous Article | Next Article 
Journal of Clinical Microbiology, July 2001, p. 2738-2741, Vol. 39, No. 7
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2738-2741.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Utility of
2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenyl-Amino)Carbonyl]-2H-Tetrazolium
Hydroxide (XTT) and Minimum Effective Concentration Assays in the
Determination of Antifungal Susceptibility of Aspergillus
fumigatus to the Lipopeptide Class of Compounds
S. P.
Hawser,1
C.
Jessup,2
J.
Vitullo,2 and
M. A.
Ghannoum2,3,*
Aventis, F-93235 Romainville,
France,1 and Mycology Reference
Laboratory, Center for Medical Mycology, University Hospitals of
Cleveland,3 and Department of Dermatology, Case
Western Reserve University,2 Cleveland, Ohio
44106-5028
Received 1 September 2000/Returned for modification 9 February
2001/Accepted 19 April 2001
 |
ABSTRACT |
The susceptibility of Aspergillus fumigatus to
mulundocandin, an echinocandin-like compound, and other antifungal
agents was assessed by the National Committee for Clinical Laboratory
Standards (NCCLS) M38-P method, a
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide (XTT)-based colorimetric assay, and determination of morphologic alterations by microscopy. In contrast to the NCCLS M38-P
method, which does not predict the activity in vivo, the XTT-based
assay showed that A. fumigatus is susceptible to
mulundocandin. Thus, the XTT-based assay might be useful for
determination of the susceptibilities of molds to echinocandins.
Further evaluation is warranted.
 |
TEXT |
The National Committee for
Clinical Laboratory Standards (NCCLS) is developing a reference method
for broth dilution antifungal susceptibility testing of filamentous
fungi (12). This method does not, however, incorporate
standardized testing of new classes of antifungal agents such as the
macrocyclic lipopeptide antifungal agents (9).
Examples of antifungal agents from the macrocyclic lipopeptide
class are caspofungins, FK463, and mulundocandin
(5). These compounds are echinocandin-like lipopeptide
antifungal agents, which are assumed to exert their antifungal activity
through the inhibition of
-(1,3)-D-glucan synthesis
(9). Mulundocandin is an echinocandin-like lipopeptide
obtained from a variant of Aspergillus sydowii
(13). It has antifungal activity against Candida strains, including fluconazole-resistant isolates,
and is being developed by Aventis (Romainville, France).
However, this compound is poorly active against other
non-Candida albicans isolates and is inactive
against Cryptococcus neoformans (5). The
biological activity of mulundocandin and structural elucidation studies
with the compound have been described previously (5, 11).
In addition to the NCCLS proposed methodology, several studies have
demonstrated the use of alternative assays that may be useful for the
susceptibility testing of fungi, including Aspergillus species. These include colorimetric susceptibility assays based upon
the use of the tetrazolium salt
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) or Alamar Blue (7, 15) and agar-based assays such as
the E-test (3). MTT has also been shown to be useful in
this context for the susceptibility testing of yeasts (2),
as has a related tetrazolium salt,
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide (XTT) (4, 6, 14). In the study described here, we have used the XTT-based assay in order to evaluate the effects of
mulundocandin on Aspergillus fumigatus in vitro and compared this technique with the microdilution and morphology assays
performed by the NCCLS M38-P method. We focused on A. fumigatus because it is the primary pathogen (responsible for
approximately 90% of human aspergillosis) causing life-threatening
invasive aspergillosis, pulmonary aspergilloma, allergic
bronchopulmonary aspergillosis, and extrapulmonary infections (for a
review, see reference 10).
The organisms used included the following clinical isolates: A. fumigatus WGHU 8896, WGHU 8901, and BP 9220 (kind gifts
from M. Richardson, Mycology Reference Laboratory, Glasgow, United Kingdom). A. fumigatus ATCC 9643, a reference strain, was
also used in our study. The isolates were grown and maintained on
potato dextrose agar slants. The susceptibilities of the isolates to mulundocandin (prepared at Aventis, Frankfurt, Germany), amphotericin B
and flucytosine (Sigma Chemical Co., St. Louis, Mo.), and fluconazole (synthesized at Aventis) were assessed by the broth microdilution technique, which is similar to the M38-P method for the susceptibility testing of filamentous fungi (12). Conidia were counted
with a hemocytometer, and 104 conidia/ml
(100-µl aliquots) were inoculated into wells of 96-well microtiter
plates containing 100 µl of RPMI 1640 medium (12). The
antifungal agents tested were amphotericin B and itraconazole (0.015 to
16 µg/ml), fluconazole and flucytosine (0.13 to 64 µg/ml), and
mulundocandin (0.1 to 256 µg/ml). The plates were incubated for
72 h at 35°C. The MICs of amphotericin B and mulundocandin were
defined as the lowest drug concentrations that caused 100% inhibition
of fungal growth compared to the growth in the control well, while for
fluconazole and flucytosine the MICs were defined as the lowest
concentrations of the antifungal agents that cause 80% inhibition
compared to the growth in the control wells. The MICs were determined
visually. The second susceptibility assay was performed as described
above, with the following additions. Three hours prior to reading of
the standard visual MIC, the plates were agitated to resuspend the cell
pellets in the wells of flat-bottom plates. Unlike the microtiter
plates with U-shaped wells used in the M38-P method, we used
flat-bottom plates in our study because such plates were used
previously in colorimetric assays (7). Thereafter, 50-µl
aliquots of a solution containing 200 µg of XTT (Sigma) per ml and 20 µg of phenazene methylsulfate (Sigma) per ml were added in order to
measure the metabolic activities of untreated (control) and antifungal
agent-treated cells. The plates were incubated for 3 h at 35°C
to allow color development. The absorbance at 492 nm was read with a
Titertek microtiter plate reader. The absorbance values for antifungal
agent-treated cells were compared with the absorbance values for
untreated control cells, and the inhibitory concentration that resulted
in an 80% reduction in metabolism (IC80) was
calculated from dose-response curves.
The effects of mulundocandin on the morphology of A. fumigatus cells were assessed by using the minimum effective
concentrations (MECs), as described previously (8).
Briefly, the plates were prepared in exactly the same way as they were
for testing by the M38-P method, and the effects of mulundocandin on
the morphologies of A. fumigatus cells were assessed by
viewing the cells under a light microscope after 18 h of
incubation at 35°C. The MEC was defined as the minimum concentration
of mulundocandin that produced morphologic alterations of A. fumigatus cells (abnormal hyphal growth with highly branched tips,
swollen germ tubes, and distended balloon-like cells). To critically
evaluate the effects of mulundocandin on the morphologies of A. fumigatus cells, the cells were examined by scanning electron
microscopy (SEM). The cells were taken from microtiter plates prepared
by the M38-P method and included untreated control cells taken from
growth control wells. Cells were also taken from wells which contained
the corresponding IC80 (see description of the
XTT-based assay above) of mulundocandin. The cells were harvested,
centrifuged, and subjected to three washes of 10 min each with 0.15 M
phosphate-buffered saline (pH 7.2). Thereafter, the cells were fixed in
3% glutaraldehyde (cacodylate buffer) for 1 h. The samples were
then washed three times (10 min each time) with buffer and postfixed in
1% OsO4 (prepared in cacodylate buffer). The
samples were dehydrated with increasing concentrations of ethanol,
immersed in hexamethyldisilazane (Sigma) for 5 min, dried, and then
sputter coated. Samples were viewed with a JEOL 480 scanning electron microscope.
Using the M38-P method, we observed that the A. fumigatus
isolates showed different susceptibilities to the antifungal agents. For example, we noted that they were poorly susceptible to
mulundocandin (MIC range, 64 to 128 µg/ml), as has also been shown in
a previous study (5). In contrast, amphotericin B (MIC
range, 0.03 to 0.12) and itraconazole (MIC range, 0.5 to 1.0 µg/ml)
were inhibitory, while fluconazole (MIC range, 16 to 64 µg/ml) and
flucytosine (MIC range, 0.5 to 16 µg/ml) exhibited poor or moderate
levels of inhibitory activity, respectively.
Previous studies have shown that tetrazolium salts are useful in
assessing more quantitatively the effects of antifungal agents in MIC
experiments (6, 14). Colorimetric methods with tetrazolium salts such as XTT and MTT are based on the fact that these salts are
taken up by living cells and are reduced by mitochondrial dehydrogenase
of the fungi to colored tetrazolium formazan products that are
determined spectrophotometrically. While both XTT and MTT are useful,
XTT provides two main advantages over MTT: it yields a water-soluble
formazan product, eliminating the need for a cell lysis step, and it
does not require dimethyl sulfoxide as a solubilizing agent for the
reduced product. Tetrazolium salts are useful for determination of
antifungal susceptibility, as they generate clear-cut endpoints based
on a visually detectable color change that is quantifiable (6,
7). Hence, using the XTT-based assay, we examined the
susceptibilities of all isolates to each of the antifungal agents.
Figure 1 shows that amphotericin B was
uniformly active against all of the isolates tested and that the XTT
IC80s for inhibition were low, in agreement with the MICs (Fig. 1). The IC80s and MICs of
fluconazole and flucytosine were very similar, with the MICs being
elevated. By contrast, by the XTT-based assay mulundocandin showed a
marked reduction in metabolism, with IC80s being
between 1/20 and 1/40 of the MIC (depending on the isolate tested)
determined by the NCCLS M38-P method. These data suggest that
mulundocandin possesses activity against Aspergillus
isolates, despite the high MICs obtained by the M38-P method. Moreover,
this in vitro susceptibility is in agreement with the in vivo data
demonstrating the efficacy of this agent in murine models of
aspergillosis (unpublished data).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Activities of antifungal agents against four A.
fumigatus isolates, as measured by the M38-P method (MIC) and
the XTT-based assay (IC80). The values are in
micrograms per milliliter; and the graphs represent the activities of
mulundocandin (A), amphotericin B (B), itraconazole (C), fluconazole
(D), and flucytosine (E).
|
|
In order to confirm our findings that mulundocandin was active in vitro
against Aspergillus isolates, we prepared similar microtiter
plates and determined the MEC. We observed that mulundocandin does
affect the morphology of Aspergillus cells when it is tested at low concentrations (sub-MICs). For example, incubation (for 18 h at 35°C) of A. fumigatus cells in the presence of
sub-MICs of mulundocandin had a significant effect on the morphology of the fungus. These cells were much shorter and malformed compared with
untreated control cells (Fig. 2). We also
noted that there was a good correlation between the MECs and the
IC80s by the XTT-based assay (Fig.
3). By contrast, the correlation of the
MIC generated by the M38-P method with either the MEC or the
IC80 was very poor (Fig. 3). Our results
are consistent with those of Chiou et al. (C. C. Chiou, N. Mavrogiorgos, and T. J. Walsh, Abstr. 40th Intersci Conf.
Antimicrob. Agents Chemother., abstr. 940, 2000), who used the
MTT-based assay to investigate the antifungal activity of echinocandin
in combination with other cell wall-active antifungal agents. Their
data showed a correlation between the values obtained by the MTT-based
assay and hyphal damage.

View larger version (87K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of mulundocandin on the morphology of A.
fumigatus WGHU 8896 hyphae. Hyphae were observed by SEM
following 18 h of incubation at 35°C in the absence (A) or
presence (B) of a sub-MIC of mulundocandin (1.0 µg/ml). The
concentration tested corresponds to the MEC for this isolate.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of the activities of mulundocandin against
four A. fumigatus isolates as determined by the
classical methods of determination of the MIC, MEC, and
IC80. All values are in micrograms per milliliter.
|
|
Overall the XTT-based antifungal assay allows one to determine the
anti-Aspergillus activities of antifungal agents of the macrocyclic lipopeptide antifungal class and other classes of antifungal molecules. Some molecules of the lipopeptide class do show
moderate or poor activity against Aspergillus spp. by the
classical MIC testing method, as was previously seen with cilofungin,
whereby the compound was inactive when it was tested by classical MIC
methods but was observed to be efficacious in a murine model of
aspergillosis (1). In the present study, mulundocandin
showed very poor activity by the M38-P method, although it was active
by both the MEC assay and the XTT-based assay. The XTT-based assay in
combination with the MEC assay might allow one to fully appreciate the
anti-Aspergillus activities of antifungal agents such as
mulundocandin. However, it is important to emphasize that the XTT-based
assay alone can determine the susceptibility of A. fumigatus
to echinocandins. Examination by SEM is not an integral part of the
test and was used in our study to critically evaluate the morphologic
changes induced by the lipopeptide. Further studies with a large panel
of filamentous fungi should be undertaken to evaluate the clinical
usefulness of the XTT-based method for determination of the
susceptibilities of these pathogens to echinocandin-like compounds.
 |
ACKNOWLEDGMENTS |
We thank Mohammad A. Hossain for critical review of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Mycology
Reference Laboratory, Center for Medical Mycology, University Hospitals
of Cleveland, 11100 Euclid Ave., LKS 5028, Cleveland, OH 44106-5028. Phone: (216) 844-8580. Fax: (216) 844-1076. E-mail:
mag3{at}po.cwru.edu.
 |
REFERENCES |
| 1.
|
Beaulieu, D.,
J. Tang,
D. J. Zeckner, and T. R. Parr, Jr.
1993.
Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)- -D-glucan synthase.
FEMS Microbiol. Lett.
108:133-138[Medline].
|
| 2.
|
Clancy, C. J., and M. H. Nguyen.
1997.
Comparison of a photometric method with standardized methods of antifungal susceptibility testing of yeasts.
J. Clin. Microbiol.
35:2878-2882[Abstract/Free Full Text].
|
| 3.
|
Colombo, A. L.,
F. Barchiesi,
D. A. McGough,
A. W. Fothergill, and M. G. Rinaldi.
1995.
Evaluation of the E test versus a microtiter broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole.
J. Antimicrob. Chemother.
36:93-100[Abstract/Free Full Text].
|
| 4.
|
Hawser, S.
1996.
Comparisons of the susceptibilities of planktonic and adherent Candida albicans to antifungal agents: a modified XTT tetrazolium assay using synchronized C. albicans cells.
J. Med. Vet. Mycol.
34:149-152[Medline].
|
| 5.
|
Hawser, S.,
M. Borgonovi,
A. Markus, and D. Isert.
1999.
Mulundocandin, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro.
J. Antibiot.
52:305-310[Medline].
|
| 6.
|
Hawser, S. P.,
H. Norris,
C. J. Jessup, and M. A. Ghannoum.
1998.
Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents.
J. Clin. Microbiol.
36:1450-1452[Abstract/Free Full Text].
|
| 7.
|
Jahn, B.,
A. Stuben, and S. Bhakdi.
1996.
Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar Blue tests.
J. Clin. Microbiol.
34:2039-2041[Abstract/Free Full Text].
|
| 8.
|
Kurtz, M. B.,
I. B. Heath, and J. Marrinan.
1994.
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)- -D-glucan synthase.
Antimicrob. Agents Chemother.
38:1480-1489[Abstract/Free Full Text].
|
| 9.
|
Kurtz, M. B., and C. M. Douglas.
1997.
Lipopeptide inhibitors of fungal glucan synthase.
J. Med. Vet. Mycol.
35:79-86[Medline].
|
| 10.
|
Latge, J. P.
1999.
Aspergillus fumigatus and aspergillosis.
Clin. Microbiol. Rev.
12:310-350[Abstract/Free Full Text].
|
| 11.
|
Mukhopadhyay, T.,
B. N. Ganguli,
H. W. Fehlhaber,
H. Kogler, and L. Vertesy.
1987.
Mulundocandin, a new lipopeptide antibiotic. II. Structure elucidation.
J. Antibiot. (Tokyo)
40:281-289[Medline].
|
| 12.
|
National Committee for Clinical Laboratory Standards.
1998.
Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 13.
|
Roy, K.,
T. Mukhopadhyay,
C. G. S. Reddy,
K. R. Desikan, and B. N. Ganguli.
1987.
Mulundocandin, a new lipopeptide antibiotic. I. Taxonomy, fermentation, isolation and characterization.
J. Antibiot. (Tokyo)
40:275-280[Medline].
|
| 14.
|
Tellier, R.,
M. Krajden,
G. A. Grigoriew, and I. Campbell.
1992.
Innovative endpoint determination system for antifungal susceptibility testing of yeasts.
Antimicrob. Agents Chemother.
36:1619-1625[Abstract/Free Full Text].
|
| 15.
|
Tiballi, R. N.,
X. He,
L. T. Zarins,
S. G. Revankar, and C. A. Kauffman.
1995.
Use of a colorimetric system for yeast susceptibility testing.
J. Clin. Microbiol.
33:915-917[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, July 2001, p. 2738-2741, Vol. 39, No. 7
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2738-2741.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shehata, A. S., Mukherjee, P. K., Ghannoum, M. A.
(2008). Comparison between the Standardized Clinical and Laboratory Standards Institute M38-A2 Method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-Tetrazolium Hydroxide- Based Method for Testing Antifungal Susceptibility of Dermatophytes. J. Clin. Microbiol.
46: 3668-3671
[Abstract]
[Full Text]
-
Mowat, E., Butcher, J., Lang, S., Williams, C., Ramage, G.
(2007). Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol
56: 1205-1212
[Abstract]
[Full Text]
-
Ahmed, A. O. A., van de Sande, W. W. J., van Vianen, W., van Belkum, A., Fahal, A. H., Verbrugh, H. A., Bakker-Woudenberg, I. A. J. M.
(2004). In Vitro Susceptibilities of Madurella mycetomatis to Itraconazole and Amphotericin B Assessed by a Modified NCCLS Method and a Viability-Based 2,3-Bis(2-Methoxy-4-Nitro-5- Sulfophenyl)-5-[(Phenylamino)Carbonyl]-2H- Tetrazolium Hydroxide (XTT) Assay. Antimicrob. Agents Chemother.
48: 2742-2746
[Abstract]
[Full Text]
-
Tunney, M. M., Ramage, G., Field, T. R., Moriarty, T. F., Storey, D. G.
(2004). Rapid Colorimetric Assay for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.
48: 1879-1881
[Abstract]
[Full Text]
-
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H.
(2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother.
48: 693-715
[Full Text]
-
Arikan, S., Paetznick, V., Rex, J. H.
(2002). Comparative Evaluation of Disk Diffusion with Microdilution Assay in Susceptibility Testing of Caspofungin against Aspergillus and Fusarium Isolates. Antimicrob. Agents Chemother.
46: 3084-3087
[Abstract]
[Full Text]